Here we report the long-term results of the DCLSG protocols ALL-6 and -7 with special emphasis on the incidence of CNS relapse after treatment without cranial irradiation. In DCLSG protocol ALL-6 (1984ALL-6 ( -1988, designed for patients with ALL non-high risk (ALL-NHR) (WBC Ͻ50 × 10 9 /l, no mediastinal mass, no B cell phenotype and no CNS involvement at diagnosis, comprising 71% of all ALL patients), CNS prophylaxis consisted of a combination of three methods of chemotherapeutic CNS prophylaxis (the use of dexamethasone during induction and maintenance therapy, i.v. medium dose methotrexate and prolonged administration of intrathecal triple therapy). Total duration of treatment: 116 weeks. 190 patients were enrolled in the study. At 10 years, the EFS rate for all patients is 81.5 ± 2.8%, the survival rate 84.8 ± 2.7%, and the cumulative incidence of isolated CNS relapse 1.1 ± 0.8%. The 10-year survival rate for the 139/190 (73.1%) patients with standard risk non-T lineage ALL according to the NCI risk criteria is 80.5 ± 3.4%. DCLSG protocol-7 was identical to the intensive ALL-BFM-86 protocol, but cranial irradiation was restricted to patients with initial CNS involvement. Patients were stratified into three risk groups (SRG, RG and EG). Treatment duration was 18 months. 218 patients were enrolled in the study. At 10 years, the EFS rate for all patients is 63.4 ± 3.3%, the survival rate 76.4 ± 3.0%, the 5-year cumulative incidence of isolated CNS relapse 5.7 ± 1.8%. The EFS rate at 10 years of the 127/218 (58.3%) patients with standard risk non-T-lineage ALL according to the NCI risk criteria was 67.9 ± 4.3%, which is not significantly different from the results achieved in this category of patients with the moderately intensive treatment according to protocol ALL-6 (logrank P = 0.17). These DCLSG studies indicate that omission of cranial irradiation does not jeopardize the overall good results. Leukemia (2000) 14, 2240-2246.
Introduction
Since 1984 the DCLSG has endeavoured to reduce long-term side-effects by omitting cranial irradiation in the treatment of the majority of children with acute lymphoblastic leukemia in The Netherlands without jeopardizing the overall cure.
The DCLSG Protocol ALL-6 (1984 ALL-6 ( -1988 was designed for children with so-called non-high risk ALL (ALL-NHR) patients, comprising 71% of all ALL patients. In this protocol all patients received the same treatment, based on Pinkel's total therapy, in which cranial irradiation was substituted by a combination of three methods of chemotherapeutic CNS prophylaxis.
In 1988, the DCLSG started to cooperate with the BerlinFrankfurt-Mü nster (BFM) group and adopted their highly effective treatment strategy for further improvement of treatment results in The Netherlands. [1] [2] [3] [4] (1988) (1989) (1990) (1991) was similar to the BFM-ALL-86 protocol with the exception that cranial irradiation was restricted to patients with initial CNS involvement. The protocol was open for all newly diagnosed patients with ALL in this period (excluding patients with B-ALL). Details of the protocols, treatment results and prognostic factor analyses have been given in earlier publications. [5] [6] [7] Here, we report the long-term results, with special emphasis on the incidence of CNS relapse. Furthermore, for comparison of the effectivity of different protocols the treatment results are evaluated according to the NCI/Rome criteria. 8 
Materials and methods
The diagnosis of ALL was made by cytomorphological and cytochemical examination of blood and bone marrow smears at the local institution, and subsequently reviewed and classified according to FAB criteria by the DCLSG laboratory. 9, 10 For the diagnosis of ALL у25% blasts in the bone marrow was mandatory. A sample of cerebrospinal fluid (CSF), mixed 1:1 with a transport medium, was sent to the DCLSG laboratory at diagnosis and when a relapse was suspected. 11 Central nervous system (CNS) involvement was defined as the presence of уfive cells/l in the CSF with leukemic blasts (cytomorphological) without major blood contamination (Ͻ17 erythrocytes/l), or leukemic infiltration of the brain, assessed by cranial computed tomography. 12 Mediastinal mass was defined as a mass of 1/3 thoracic diameter at the level of the 5th thoracic vertebra. The leukemic cell mass estimate, the BFM risk factor RF, was calculated by the equation: RF = 0.2 × log (number of peripheral blood blasts/mm 3 + 1) + 0.06 × liver cm below costal margin + 0.04 × spleen cm below costal margin. 1, 2 Immunophenotyping was performed by the DCLSG laboratory if cytospin bone marrow smears contained у60% blasts. Immunological markers were judged positive if expressed in у20% of the malignant cells.
A leukemia was classified as precursor B-ALL if the malignant cells were positive for TdT, CD19 and HLA-DR (pro-B ALL), or for TdT, CD10, CD19 and HLA-DR (common ALL), or for TdT, CD10, CD19, HLA-DR and CyIg (pre-B-ALL). A T-ALL was defined by positivity for TdT, CD2, cytoplasmic CD3 (CyCD3) and/or CD7. Acute undifferentiated leukemia (AUL) was defined if common-ALL, pre-B, T cell characteristics and also myeloid markers were negative. Cytogenetic analysis was carried out by members of the Dutch Working Party on Cancer Genetics and Cytogenetics at the various Clinical Genetics Centers in The Netherlands. All findings were peer-reviewed before submission to the database. 13 An abnormal clone was defined as a minimum of two metaphases with the same structural abnormality or additional chromosome, or three metaphases with the same missing chromosome. Cytogenetic analysis was considered a failure if less than 20 metaphases with an apparently normal karyotype from an unstimulated or unsynchronized culture had been analyzed. Cell ploidy was based on cytogenetic findings. The DNA index was measured by the Department of Experimental Therapy of The Netherlands Cancer Institute (Amsterdam).
Treatment and treatment stratification (Table 1)
Informed consent was obtained according to institutional guidelines before treatment and, if applicable, before randomization. An outline of the protocols and treatment stategies is shown in Table 1 .
In DCLSG Protocol ALL-6 ALL-NHR was defined as: initial white blood cell count (WBC) Ͻ50 × 10 9 /l, absence of a mature B cell phenotype, a mediastinal mass and cerebromeningeal leukemia at diagnosis. (All other patients were considered to have high-risk ALL and were treated according to institutional protocols; they are left out of this analysis.) Induction treatment consisted of vincristine (VCR), dexamethasone (DXM) and l-asparaginase (l-Asp) and two intrathecal (IT) injections of methotrexate (MTX) and prednisolone (PDN). A combination of three methods of CNS prophylaxis was applied: the use of DXM (6 mg/m 2 /day orally) in induction and in pulses (DXM and VCR) during maintenance, intravenous medium-dose MTX (MD-MTX) (2 g/m 2 in 24 h for three courses) with citrovorum factor after 36 h and IT MTX and PDN (×3), and prolonged (×8) administration of triple intrathecal therapy (PDN, MTX and cytosine arabinoside (Ara-C) during the first year of maintenance (6-mercaptopurine (6-MP) and MTX). The total duration of treatment was 116 weeks. One hundred and ninety patients were enrolled in the protocol.
In Protocol ALL-7 patients were stratified into three groups: a standard risk group (SRG), defined as RF Ͻ0.8, without mediastinal mass, CNS involvement or EG characteristics (30% of all patients); a risk group (RG) was defined as RF у0.8 and/or mediastinal mass and/or CNS involvement, without EG NHR, non-high risk; SRG, standard risk group; RG, risk group; EG, experimental group; VCR, vincristine; DXM, dexamethasone; DNR, daunorubicin; L-Asp, L-asparaginase; Cyclo, cyclophosphamide; ara-C, cytosine arabinoside; 6-MP, 6-mercaptopurine; MTX, methotrexate; HD, high dose; PDN, prednisone; ADR, adriamycin; VDS, vindesine; IFO, ifosfamide; MITOX, mitoxantrone; 6-TG, 6-thioguanine; VM-26, teniposide; IT, intrathecal; MD, medium dose; i.v., intravenous.
Leukemia characteristics (60% of all patients) and an experimental group (EG) which was independent of the risk factor, comprising patients with immunophenotypically acute undifferentiated leukemia, and/or у1000/mm 3 blood blasts on day 8 after 7 days of monotherapy with prednisone (poor prednisone response) and/or no CR after (the first part of) protocol I (day 42) and/or leukemic blasts karyotype t(9;22) or t(4;11) (10% of all patients). All patients received intensive induction treatment according to the so-called protocol I for 10 weeks, consisting of PDN, VCR, daunorubicin (DNR), l-Asp, Ara-C, cyclophosphamide (Cyclo), 6-MP and intrathecal therapy (MTX, ×3). After protocol I, all children received protocol M: four doses of intravenous high-dose metothrexate (HD-MTX) (5 g/m 2 , 24-h infusion, every 2 weeks) in combination with oral 6-MP and intrathecal therapy (MTX, ×4). For EG patients protocol M was intensified with PDN, HD-Ara-C, ifosfamide (IFO), mitoxantrone (MITOX) and intrathecal therapy (MTX, ×4) (protocol E).
After protocol I and M/E, RG and EG patients received protocol II: dexamethasone (DXM), VCR, adriamycin (ADR), lAsp, Ara-C, 6-thioguanine (6-TG) and intrathecal therapy (MTX ×2). All patients received maintenance treatment with MTX and 6-MP. The total duration of treatment was 18 months. Patients 1 year of age and older with initial CNS involvement received cranial irradiation (18 Gy). Infants were not irradiated, regardless of the CNS status. EG patients in CR with a matched sibling donor were offered allogeneic bone marrow transplantation after protocol E. Since treatment results in SRG patients (treated without protocol II) turned out to be inferior to historical results in BFM protocols, protocol II was introduced to The Netherlands in the treatment of SRG patients diagnosed from October 1990 (SRT patients). RG patients who were in continuous complete remission (CCR) after 1 year were randomized to receive (group 2) or not to receive (group 1) protocol S, consisting of Pred, vindesine (VDS), teniposide (VM26), IFO and HD-Ara-C.
In DCLSG protocol ALL-7, 218 patients were enrolled: 74 SRG patients (30 of them received protocol II (SRT); 44 patients did not (SRG)), 127 RG patients (51 randomized; 25 into SR1, 26 into SR2) and 17 EG patients.
Statistical analysis
The duration of event-free survival (EFS) is defined as the time from attainment of a complete remission until the date of failure (relapse, death, or the development of a second malignancy) for those patients who failed, or until the date of last contact for those patients who did not fail. Patients who did not attain a complete remission were considered failures at time zero. Duration of continuous complete remission (CCR) is EFS conditional upon achieving a complete remission. Distributions of EFS and CCR were estimated by the method of Kaplan and Meier and were compared using the logrank test. All analyses were performed on the basis of 'intent-to-treat' and thus only patients who remain failure-free are censored at last contact. Cumulative incidence functions of isolated CNS and CNS relapse were constructed by the method of Kalbfleish and Prentice 14 for patients who achieved a complete remission. Relapse is defined as у25% blasts cells in the bone marrow and/or blasts cells in the peripheral blood, and/or CNS involvement, and/or leukemic infiltration(s) elsewhere. An isolated CNS relapse is defined as a CNS relapse without relapse at other sites or another type of failure. A CNS relapse is defined as an isolated CNS relapse or a CNS relapse in conjunction with another type of relapse or failure. In the estimation of these cumulative incidence functions all other failures are considered competing events. The database for all analyses was 'frozen' on 1 March 2000.
Long-term follow-up
The follow-up procedures of the DCLSG have been described previously. All smears of (at that time) routine bone marrow punctures (every 3 months) were examined at the DCLSG laboratory. Registration forms with data on dosage, toxicity and results of treatment for each patient were sent to the DCLSG Operations Office on a regular base: every 3 months during maintenance treatment, every 1-2 years after cessation of treatment.
At the time of this analysis, reports on remission and survival status of approximately 55% of the 154 event-free survivors on protocol DCLSG ALL-6 and of approximately 85% of the 140 event-free survivors on protocol DCLSG ALL-7 had been received at the DCLSG Operations Office after 1 January 1998. Five patients were lost to follow-up. (Figures 1-3 ; Tables 2-4) DCLSG Of the 190 patients enrolled, 184 (96.8%) attained a complete remission. The overall event-free survival at 5 and 10 years was 82.6 ± 2.7% and 81.5 ± 2.8%, respectively, the survival rate 89.5 ± 2.2% and 86.1 ± 2.2%, respect- DCLSG-ALL-6: EFS and cumulative incidence of CNS relapse.
Results

Protocol-specific treatment outcome
ively ( Table 2 ). The proportion of patients in continuous complete remission (CCR) was 84.1 ± 2.7%. Twenty-six patients relapsed (23 patients suffered from bone marrow relapse, two from CNS relapse and one male suffered from testicular relapse), four patients died in remission (cause of death: septicemia (two patients), fungal cerebral abscesses (one patient) and of sudden death, cause unknown (one patient).
The median (minimum, maximum) follow-up duration for patients remaining event-free was 10.9 (6.0, 14.4) years. The cumulative incidence of isolated CNS relapse at 5 and 10 years was the same: 1.1 ± 0.8% (Figure 1 ). Combined CNS relapses did not occur. No significant prognostic factors (age, gender, WBC, platelet counts, DNA index, day 12 bone marrow findings) could be identified.
DCLSG ALL-7:
Complete remission was achieved in 212 (98%) patients (five patients failed to achieve remission; one patient was not evaluable, because of missing data). The overall event-free survival at 5 and 10 years was 65.3 ± 3.2% and 63.4 ± 3.3% respectively, and the survival rate 77.8 ± 2.8% and 76.4 ± 3.0%, respectively (Table 4 ).
Figure 2
DCLSG-ALL-7: EFS and cumulative incidence of CNS relapse.
Figure 3
DCLSG-ALL-7: EFS, all events included. Sixty-five patients relapsed (47 patients suffered from bone marrow relapse, 12 patients from isolated CNS relapse, three patients from a combined bone marrow and CNS relapse and three patients suffered from relapses at other sites). Six patients died in remission (cause of death: septicemia (two patients), interstitial pneumonia (one patient) and complications of bone marrow transplantation (three patients)), in two patients a second malignancy was diagnosed (thyroid carcinoma, acute non-lymphoblastic leukemia).
The median (minimum, maximum) follow-up duration for patients remaining event-free was 8.75 (4.1, 11.2) years. The 5-year cumulative incidence of isolated CNS relapse was 5.7 ± 1.8% and that of CNS relapse 7.1 ± 2.0% (Figure 2) . The proportion of patients in continuous complete remission at 5-year for SRG, RG and EG patients were 63.5 ± 5.6%, 66.6 ± 4.2% and 63.3 ± 12.3%, respectively. SRG patients receiving protocol II fared better than patients not receiving protocol II (proportion in CCR at 5 years was 76.7 ± 7.7% (SRT) and 54.5 ± 7.5% (SRG), respectively (logrank P = 0.049) and none of the 30 SRG patients receiving protocol II suffered from CNS Table 3 Treatment results of DCLSG protocol ALL -7 (1988-1991) relapse, compared to five of the 44 patients not receiving protocol II. A randomized study on the effectiveness of late intensification with protocol S showed no significant difference in the outcome for RG patients. Six patients underwent allogeneic bone marrow transplantation: two patients are in CCR, 8 and 9 years respectively, after BMT; four patients died: one patient died after relapse, three patients died of transplantation-related toxicity. None of the factors tested (sex, age, WBC, Hb, FAB-type, immunophenotype, DNA-index, ploidy, prednisone response) proved to be of significant prognostic influence.
Treatment results according to presenting features in each era (Table 4)
The majority of the eligible, consecutive patients in each treatment era was included in the protocol: 190 of 206 (92%) ALL-NHR patients in the ALL-6 era and 218 of 259 (84%) ALL patients in the ALL-7 era. No significant differences were observed between the patient and disease characteristics of protocol and non-protocol patients. (For ALL-6 this comparison concerns only ALL-NHR patients.) For the evaluation of the treatment results of protocol DCLSG-ALL-7 according to the NCI/Rome criteria, 13 treatment results achieved in SRG patients treated without protocol II have been left out of Table  3 (n = 44), since nowadays protocol II is considered an essential part of BFM-oriented treatment, but are included in a separate analysis (Table 4 ). The overall treatment results of Protocol ALL-7, including a prognostic factor analysis, which included both SRG and SRT patients, have been published previously.
6 None of the factors tested (sex, age, WBC, hemoglobin value, FAB type, immunophenotype, DNA index, ploidy and prednisone response) were of significant influence on the outcome. In The Netherlands, the race of the patients is not registered and therefore is not part of this analysis. Karyotyping on a nationwide scale had just been started during the ALL-6 study and these data are rather incomplete and therefore left out; only karyotypes of the ALL7 patients are reported. Finally, the day 15 bone marrow was not examined in the DCLSG-ALL-7 study.
Discussion
The long-term results of Protocol ALL-6 with an EFS rate at 10 years of 80.5 ± 3.4% remain very satisfactory. The substitution of cranial irradiation by a combination of three methods of CNS prohylaxis (the use of DXM (6 mg/m 2 /day orally) in induction and in pulses (DXM and VCR) during maintenance, intravenous medium-dose methotrexate (MD-MTX) (2 g/m 2 in 24 h for three courses) with citrovorum factor after 36 h, and prolonged (×8) administration of triple intrathecal therapy (prednisolone (PDN), MTX and cytosine arabinoside (ARA-C) during the first year of maintenance (6-mercaptopurine (6-MP) and MTX)) prevented CNS relapse in approximately 99% of the ALL-NHR patients. In the ALL6 study no prognostic factors could be identified. However, due to the small study size, there is a chance of missing moderate to small differences. In the current DCLSG Protocol ALL-9 the same treatment is applied in a much larger number of ALL-NHR patients and this study may render additional data.
Dexamethasone (DXM) has made a major contribution to the prevention of CNS relapse, which also appears from the treatment results in ALL7-SRG patients: no CNS relapses occurred in ALL-SRG patients who received protocol II, which includes DXM, compared to five of 44 patients who did not receive protocol II. However, other treatment modalities (prolonged intrathecal therapy, medium or high doses of intravenous chemotherapy) may also be important in this respect.
Despite the large doses of DXM applied to patients treated according to ALL6 a representative number of long-term survivors of Protocol ALL-6 showed normal bone mineral density, body composition and heights. 15 The results of DCLSG Protocol ALL-7 have shown that that systemic high-dose methotrexate and intrathecal chemotherapy is a safe and effective substitute for cranial irradiation as CNS prophylaxis in BFM-oriented treatment for all children with ALL, regardless of the risk group (with the possible exception of T cell ALL patients with high WBC). 7, 16 For NCI standard risk ALL patients, long-term treatment results tend to be better after using Protocol ALL-6 (EFS at 10 year 80.5 ± 3.4%) than after the intensive BFM oriented treatment according to Protocol ALL7 (EFS at 10 year 71.5 ± 4.9%) (logrank P = 0.17), in which anthracyclines and alkylating agents are applied. The total duration of therapy was 116 weeks in Protocol ALL-6, compared to 78 weeks in Protocol ALL7. It can be hypothesized that for this category of patients prolonged, less intensive treatment according to protocol ALL-6 is superior to shorter, more intensive BFM-oriented treatment according to Protocol ALL7.
